Introduction
According to 2013 World Health Organization statistics for Mycobacterium tuberculosis (MTB) in India, approximately 2.1 billion cases have been reported out of global incidences of 9 million TB cases. Such high incidences of TB in India indicate a need for better health habits and food quality to prevent its spread [1] . Initially, TB treatment was possible using conventional antibiotics, however, the scenario has worsened due to the emergence of drug-resistant MTB. The phenomena of drug resistance began with multidrug resistant tuberculosis, followed by the discovery of extensively drug-resistant TB and total drug-resistant TB. Acquisition of resistance to many antibiotics makes this bacterium difficult to treat [2] . MTB mostly causes lung infections, but also infects other organs, such as the kidneys, lymph nodes, joints, vertebral column, and even the spleen.
Mycolic acids are hydroxyl fatty acids with long alkyl side chains. They are found in the cell wall of Mycolata taxon, which includes MTB, and increase resistance against chemical damage and dehydration, allowing the bacteria to readily grow inside macrophages and protect themselves against host immune systems. Mycolic acids are crucial for bacterial existence and maintenance of pathogenicity. MTB expresses and secretes three closely related mycolyl transferases with masses between 30 kDa and 35 kDa, known as antigen-85 http://dx.doi.org/10.1016/j.ijmyco.2015.07.002 2212-5531/Ó 2015 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd. All rights reserved.
protein complexes (Ag85A, Ag85B, and Ag85C), which are involved in the biogenesis of MTB cell walls. Given their vital role in cell wall synthesis, they are considered an ideal target for therapeutic treatment against TB [3] . These proteins catalyze the transfer of mycolic acid from one trehalose 6-monomycolate (TMM) to another, forming trehalose 6,6-dimycolate (DMM) and free trehalose.
Antimicrobial peptides (AMPs) are short stretches of amino acids made up of less than 50 amino acid residues with a molecular weight of between 2 kDa and 12 kDa and a broad spectrum of antimicrobial activity. AMPs can be cationic, anionic, or neutral are a key component of the innate immune system present in multicellular organisms [4] . A large number of AMP families are produced in animals, with the two main families called defensins and cathelicidins. AMPs exhibit broad spectrum antimicrobial activity. One advantage is that microbes do not easily gain resistance to them due to their nonspecific binding to the cell membrane. Therefore, they can be used to treat infections caused by organisms that are resistant to conventional antibiotics, i.e., drug resistant. Dermcidin is an AMP encoded by the DCD gene (NM_001300854.1) in humans. It is secreted by sweat gland cells to provide a barrier function [5] . Dermcidin display a broad spectrum of antimicrobial activity against both Gram-positive and Gram-negative bacterial pathogens [6] . The present study was undertaken in order to understand the inhibitory effect of dermcidin on mycolyl transferase by means of in silico studies.
Materials and methods

System requirements
The entire study was performed on a Sony Vaio Laptop with a 2.67 GHz processor, 4 GB RAM, and a 320 GB hard drive and a Windows Professional operating system. All software used for the present study were open-source tools available free for download.
Receptor molecule fibronectin-binding protein A (FbpA) MTB expresses three mycolyl transferase enzymes that are closely related and together constitute an Ag85 complex. They are involved in cell wall synthesis by catalyzing the reaction between TMM and mycolic acid to form DMM, also called a cord factor, which is a structure necessary for maintaining cell wall integrity [7] . They are also involved in transformation of mycolic acid from TMM to arabinogalactan for the peptidoglycan layer of the cell wall, ultimately forming an arabinogalactanmycolate polymer [8] . The structure of mycolyl transferase, also known as FbpA, was retrieved from the Protein Data Bank (PDB ID: 1SFR) [9] . FbpA is an enzyme with a molecular weight of 35.68 kDa, a pI of 6.51, and consisting of 304 amino acid residues. Data were also obtained from the tuberculist database (http://tuberculist.epfl.ch/; RV number: 3804c) [9, 10] .
Ligand molecule
In the present study, dermcidin AMP was used as a ligand molecule. Dermcidin is a peptide of 110 amino acid residues that is cleaved by proteases present in human sweat to produce peptides of varying length and diverse function. The dermcidin C-terminal peptide possesses antibacterial and antifungal activity and is constitutively expressed in sweat, while the N-terminal peptide promotes survival of neural cells under conditions of severe oxidative stress. The amino acid sequence of the C-terminal peptide is NH 2 -SSLLEKGLD GAKKAVGGLGKLGKDAVEDLESVGK-COOH and was used in the present study to generate the protein model. The protein model was generated using the SWISS MODEL online web tool. (http://swissmodel.expasy.org/) [11] . SWISS MODEL is a fully automated protein structure homology modeling server. Based upon query coverage and a Global Model Quality Estimation (GMQE) score, a template was selected to model the protein. GMQE estimates the quality of the generated protein model, which combines properties from the target-template alignment [12] .
Docking software
Four different docking software tools were used. Discovery Studio 4.1 is software developed by Accelrys (Dassault Systemes, BIOVIA Corp., San Diego, CA, USA) for creating smallmolecule structures, as well as macromolecules. A Molecular Graphics Laboratory (MGL) tool (The Scripps Research Institute, La Jolla, CA, USA) was used for the visualization and analysis of molecular structures. AutoDock (The Scripps Research Institute) is a docking tool used to predict the interaction between small molecules, such as drug compounds or substrates, with the three-dimensional structure of a molecule. Docking between Mycolyl transferase (FbpA-receptor) and dermcidin AMP (ligand) was performed using AutoDock Vina. Docked structures were visualized using the open source, molecular visualization system PyMol 1.7.4 (Schrö dinger, LLC, Cambridge, MA, USA).
Docking protocol
The receptor and ligand molecules were prepared for docking using Discovery Studio 4.1 [Dassault Systè mes BIOVIA, Discovery Studio Modeling Environment, Release 4.5, 2015] . FbpA molecule was opened using Discovery Studio, after which water molecules and other bound ligand molecules were removed. The binding site was defined after adding hydrogen molecules to the FbpA receptor molecule in order to describe the receptor cavity. FbpA (receptor) and dermcidin (ligand) molecules were saved as PDB files, then opened in the AutoDockTools portion of MGL 1.5.6 (The Scripps Research Institute) in order to prepare the receptor and ligand molecule for docking. Docking was performed using AutoDock Vina [13] and docked models visualized using PyMol (Schrö dinger, LLC).
Results and discussion
Model validation
The AMP selected in the present study is dermcidin, which was confirmed by matrix-assisted laser desorption/ionization mass spectrometry analysis. Dermcidin is an AMP with 110 amino acid residues. Following secretion, it undergoes postsecretory proteolytic processing by proteases, creating small peptides of between 25 and 48 amino acid residues [14] . A model of dermcidin was generated based on 100% query coverage using the template molecule (PDB ID: 1KSG) [15] . The generated model was validated based on parameters mentioned in Section ''Materials and methods".
Ramchandran plot
The Ramchandran plot for the template molecule was retrieved from the PDB and the plot for the modeled protein was also generated. Structural evaluation was performed using RAMPAGE (http://mordred.bioc.cam.ac.uk/~rapper/ rampage.php). Ramchandran plot analysis for the modeled protein revealed that 98% of the residues localized within favored regions, suggesting good quality of the model (Fig. 1) .
GMQE score
The GMQE score is generated by the target-template alignment of the modeled protein and the value is expressed as a number between zero and one. Higher GMQE scores indicate increased structural reliability [11] . The GMQE score for the modeled protein was found to be 0.98, which indicates good model accuracy.
Structural visualization
Structures of the template molecule and modeled molecules were visualized as described in Section ''Materials and methods" and compared for structural variation (Fig. 2) .
Enzyme active site
The Ag85A, Ag85B, and Ag85C complexes have mycolyl transferase activity that catalyze glycolipid synthesis of the mycobacterial cell wall, called the cord factor, and are also known as FbpA, FbpB, and FbpC. FbpA is a trimer consisting of three identical polypeptide chains (A, B, and C) of 304 amino acid residues each (Fig. 3A) . In a previous study by Ronning et al. (2004) [9] , OSG-octylthioglucoside was used as a substrate for Ag85C, given its similarity to a portion of the AG85C natural substrate trehalose-monomycolate. They studied the structure of Ag85C using OSG-octylthioglucoside 
as a substrate in order to obtain information regarding substrate binding and its interaction with the active site. Data revealed two types of interactions taking place between OSG-octylthioglucoside and Ag85C: van der Waals contacts and hydrogen bonds. Trp-158, Leu-161, Ile-163, and Ala-165 are involved in van der Waals interactions between OSGoctylthioglucoside and Ag85C. Gly-39 and Arg-41 are involved in the formation of hydrogen bonds with the glucose moiety of the substrate and the side chains of Asp-38, Asn-52, and Trp-262 residues located within 5.4Å of the substrate, as well as interactions with the disaccharide ring of the carbohydrate moiety [9] . Here, FbpA was selected as a target for ligand binding. The FbpA receptor cavity is shown in Fig. 3B . The amino acid residues involved in formation of the receptor cavity are shown in Table 1 . Approximately 45 amino acid residues are involved in the formation of the FbpA receptor cavity. Over 50% of the residues have hydrophobic side chains and are involved in hydrophobic interactions. The receptor cavity is being formed between chains A and B (Fig. 3B) , so only the Gln  157  31  Phe  228  2  Gly  41  17  Pro  161  32  Leu  229  3  Leu  42  18  Thr  162  33  Glu  230  4  Arg  43  19  Leu  163  34  Gly  231  5  Leu  125  20  Ile  164  35  Phe  232  6  Ser  126  21  Gly  165  36  Val  233  7  Met  127  22  Leu  166  37  Arg  234  8  Ala  128  23  Ala  167  38  Thr  235  9  Ala  129  24  Met  168  39  Ser  236  10  Ser  130  25  Gly  169  40  Asn  237  11  Ser  131  26  Asp  170  41  Ile  238  12  Ala  132  27  Leu  224  42  Lys  239  13  Leu  133  28  Pro  225  43  Phe  240  14  Thr  134  29  Ala  226  44  Gln  241  15  Asp  154  30  Lys  227  45 Asp 242 residues of chains A and B are involved in receptor cavity formation.
Docking study
The docking of FbpA with dermcidin AMP was performed by AutoDock Vina, generating nine different poses ( Table 2 ). The pose with best fit was selected based on having the lowest binding energy associated with interactions with the ligand molecule. In the present study, 5.6 kcal/mol was found to be the lowest energy value relative to other results and, therefore, was considered to represent the best fit model. The docked model was visualized using PyMol (Fig. 4) . FbpA binding to dermcidin involves 13 hydrogen bonds between substrate and FbpA residues (Table 3) . Of these 13 residues, six are involved with receptor cavity formation, confirming localization of dermcidin binding within the receptor cavity (Table 3) in the cleft between FbpA chains A and B (Fig. 4 
Conclusion
The present study concludes that dermcidin binds with FbpA to inhibit mycolic acid transfer to the peptidoglycan layer of the cell wall, interfering with cell wall synthesis. 
